Directional Bilateral Thalamic Patterned Stimulation (Chronos)

Last updated: October 31, 2024
Sponsor: Alfonso Fasano
Overall Status: Active - Recruiting

Phase

N/A

Condition

Essential Tremor

Dystonia

Treatment

DBS programing

Clinical Study ID

NCT06325852
22-5772
  • Ages 18-85
  • All Genders

Study Summary

Population Size and Eligible Patients: The investigators aim to recruit 5 to 10 patients with tremors who have previously undergone Ventral Intermedius Deep Brain Stimulation (VIM-DBS) treatment but have experienced early or late loss of benefits. Additionally, the investigators will enroll ten patients with essential tremor who require VIM-DBS surgery. These individuals will undergo bilateral implantation of Boston Scientific Genus Implantable Pulse Generator (IPG) devices, connected to Boston Scientific Cartesia™ 8-contact Directional Leads.

Study Design: This study comprises two distinct phases. Phase 1 is a cross-sectional investigation designed to identify the optimal algorithm for patterned stimulation in the VIM region . Phase 2 is a prospective clinical trial focusing on the assessment of safety and efficacy of bilateral VIM-DBS in patients with essential tremor.

Objectives: The primary objective in Phase 2 is to evaluate the safety and effectiveness of bilateral VIM-DBS in individuals with essential tremor. In Phase 1, the investigators seek to explore the impact of the Chronos programming software on tremor patients who have experienced early or late loss of benefits.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Phase 1: 5 to 10 tremor patients already treated with VIM-DBS but not doing well dueto early and/or late loss of benefits (i.e. tremor scores ON stimulation identicalor greater than before surgery in absence of stimulation).

  2. Phase 2: 10 Essential Tremor patients in need of DBS surgery.

  3. Written and signed Informed Consent.

  4. Age 18 to 85 years old.

  5. Subject must have Essential Tremor, as defined by all the following criteria: (a)isolated tremor syndrome consisting of bilateral action tremor; (b) at least threeyears duration; and (c) with or without tremor in other locations (e.g., head,voice, or low limbs) [1].

  6. Soft signs (categorizing patients as Essential Tremor-plus) will be allowed andnoted in the patient's chart.

  7. Subject must be on stable dose of anti-tremor medication for at least 4 weeks priorto screening.

  8. Subject had no botulinum injection for at least three months prior to screening.

  9. Subject does not have a significant other medical condition biasing the studyfinding in investigator's opinion.

Exclusion

Exclusion Criteria:

  1. Unwilling or inability to follow the procedures specified by the protocol.

  2. Presence of significant psychiatric or cognitive condition likely to compromise thesubject's ability to comply with requirements of the study protocol.

  3. Untreated clinically significant depression.

  4. Any current drug or alcohol abuse, as determined by the investigator.

  5. History of suicidal attempt within the last 1 year prior to consent or currentactive suicidal ideation as determined by the investigator.

  6. Any significant medical condition that is likely to interfere with study proceduresor likely to confound evaluation of study endpoints.

  7. Any terminal illness with life expectancy of < 12 months.

  8. Participation in any other interventional clinical trial (e.g. drug, device).

Study Design

Total Participants: 15
Treatment Group(s): 1
Primary Treatment: DBS programing
Phase:
Study Start date:
July 16, 2024
Estimated Completion Date:
January 01, 2027

Connect with a study center

  • Movement Disorders Centre - Toronto Western Hospital

    Toronto, Ontario M5T 2S8
    Canada

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.